PHARMA MAR news, videos and press releases
For more news please use our advanced search feature.
PHARMA MAR - More news...
PHARMA MAR - More news...
- PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
- PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
- PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan
- Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line
- PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca™) for the Treatment of Metastatic Small Cell Lung Cancer
- PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19
- PharmaMar will submit NDA for lurbinectedin under accelerated approval in SCLC in the USA
- Positive results of lurbinectedin Phase II trial (PharmaMar) for the treatment of relapsed small cell lung cancer are presented at ASCO
- Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
- PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer
- PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares
- PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
- The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
- PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
- PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
- PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International
- PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
- PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018
- Positive Recommendation of IDMC to Zepsyre® to Continue the Phase III Trial Within Small-cell Lung Cancer (ATLANTIS)
- PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018
- Sylentis Announces New Data on the Treatment of Allergic Conjunctivitis
- Sylentis Presented New Results for the Treatment of Age Associated Macular Degeneration
- Sylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye Syndrome
- Sylentis Presents New Results on Its Ophthalmological Compounds at ARVO 2018
- PharmaMar Discovers New Data on the Mechanism of Action of Plitidepsin in Tumor Cells
- PharmaMar Announces Participation at the 17th Needham & Co Annual Healthcare Conference in New York City
- PharmaMar's Lurbinectedin ATLANTIS trial design and data in small-cell lung cancer will be an oral presentation at the IASCLC´s annual meeting
- PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
- PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates
